BioCentury | Oct 19, 2018
Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

...four other discontinued new molecular entities were in Phase I testing, including cancer candidates RG7741 (ARRY-575...
...combinations with PD-L1 inhibitor Tecentriq atezolizumab and CD40 antibody selicrelumab (RG7876). Roche gained rights to RG7741...
BioCentury | Oct 17, 2018
Company News

Roche culls pipeline, cuts include in-licensed, acquired programs

...four other discontinued new molecular entities were in Phase I testing, including cancer candidates RG7741 (ARRY-575...
...combinations with PD-L1 inhibitor Tecentriq atezolizumab and CD40 antibody selicrelumab (RG7876). Roche gained rights to RG7741...
...grow in the mid-teens over 2017. Consensus figures provided by FactSet. Alicia Parker AK3280 (RG6069, GDC-3280) ARRY-575, GDC-0575, RG7741 BITS7201A...
BioCentury | Aug 16, 2017
Distillery Therapeutics

Cancer

...treat cancer, lymphoma and solid tumors, and have the Chk1 inhibitor ARRY-575 ( GDC-0575 ; RG7741...
BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: Checkpoint kinase 1 (Chk1; CHEK1)

...BioPharma Inc. have the Chk1 inhibitors GDC-0425 ( RG7602 ) and ARRY-575 ( GDC-0575 ; RG7741...
BioCentury | Oct 26, 2015
Strategy

Collaborating on combos

...of asset at deal Current status of combo Licensing Deals Array BioPharma Inc. (NASDAQ:ARRY) GDC-0575 (ARRY-575...
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: Checkpoint kinase 1 (Chk1; CHEK1); MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2); K-Ras (KRAS); BRAF

...and neck cancer. Roche 's Genentech Inc. unit and Array BioPharma Inc. have GDC-0425 and ARRY-575...
BioCentury | Aug 6, 2012
Clinical News

ARRY-575: Phase I started

...Genentech unit began an open-label, international Phase I trial to evaluate multiple ascending-doses of oral GDC-0575...
...South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: ARRY-575 , GDC-0575 , RG7741...
BioCentury | Aug 22, 2011
Strategy

Checkpoint match

...RG7602 ) is in Phase I testing to treat cancer. An IND for Array's ARRY-575...
...would have in-licensed Array's program and stopped work on its own. Array began negotiations for ARRY-575...
...DNA repair mechanism from reducing efficacy. Both GDC-0425 and ARRY-575 are dosed orally. Koch said ARRY-575...
BioCentury | Aug 15, 2011
Company News

Array BioPharma, Roche deal

...deal includes Genentech's GDC-0425 ( RG7602 ), which is in Phase I testing, and Array's ARRY-575...
BioCentury | Aug 15, 2011
Finance

Highlights of weekly biotech stock moves

...deal includes Genentech's GDC-0425 ( RG7602 ), which is in Phase I testing, and Array's ARRY-575...
Items per page:
1 - 10 of 11